Content |
Akrus BioMed LLC was registered in Moscow in July 2018, since 2019 it has been a resident of the SEZ. The company specializes in research and development in the field of biotechnology.
History
2022
Launch of production of biologics for skin healing in Moscow for 320 million rubles
As it became known at the end of October 2022, the resident of the special economic zone (SEZ) "Technopolice Moscow" "Akrus Biomed" completed the full cycle of development of biomedical cell products (BMCP) for the treatment of long-term unhealthy wounds, ulcers and extensive burns and launches their production.
According to the developers, drugs that have no direct analogues in were Russia created in cooperation with the Institute of Development Biology. N.K. Koltsov RAS. They are developed on the basis of grown human skin cells and a special carrier for the treatment of long-term non-healing wounds, ulcers and extensive burns, combined lesions. MMCPs allow you to restore skin in a short time and without formations scarring.
It is argued that treatment using domestic BMCPs will be cheaper than existing methods and more affordable both for patients and for the health care system as a whole.
According to Vladimir Efimov, Deputy Mayor of Moscow for Economic Policy and Property and Land Relations, the company has invested over 320 million rubles in the implementation of its project at the Pechatniki site. The new production and its products meet all the established requirements, added Gennady Degtev, General Director of the Technopolice Moscow SEZ.
The company expects to supply about 6 thousand products per month. Shipments to medical institutions of the capital are planned by prior order in two days
About 60 highly qualified specialists will be able to work in production. In the near future, a resident of the SEZ of Moscow intends to expand the production of BMKP and register a wide list of new drugs of this type, including for the elimination of scarring and treatment of cancer, rehabilitation after brain infarcts, severe diseases and COVID-19.[1]
Completion of the construction of the plant for 240 million rubles
On June 22, 2022, it became known about the completion of the construction of a plant for the production of drugs for cell therapy in the SEZ "Technopolice Moscow." This is a project of the company "Akrus BioMed," which invested about 240 million rubles in it .
It is planned to produce up to 70 thousand biomedical cell products (BMCP) per year at the enterprise's facilities, used to treat long-term healing wounds, ulcers and extensive burns. In the future, the company's products are planned to be supplied to the capital's clinics, burn centers and disaster medicine centers, said Vladimir Efimov, Deputy Mayor of Moscow for Economic Policy and Property and Land Relations.
It is noted that the new production will meet modern GMP cleanliness standards. The company will use multi-stage air filtration systems, as well as ultraviolet radiation.
 | A dispatching project has been implemented at the production site. One technical specialist in real time will be able to control various parameters - from temperature and pressure inside clean rooms to monitoring systems and fire protection elements, - explained Maxim Suchkov, chief engineer of Akrus BioMed. |  |
At the plant of the company "Akrus BioMed," which is expected to open in the fall of 2022, 50 people will work. The company occupied a plot of land with an area of 820 square meters. m, said Gennady Degtev, general director of the special economic zone "Technopolice 'Moscow."
According to the procedure for licensing the production of biomedical cell products (BMCP) approved by the government, the licensee must have a platform that complies with the regulations and rules of good practice for the production of BMCP, an agreement for obtaining biomaterial for the production of BMCP from medical institutions and a staff of certified employees.[2]
Notes
| The site content is translated by machine translation software powered by PROMT. The machine-translated articles are not always perfect and may contain errors in vocabulary, syntax or grammar. Read original article If you find inaccuracies or errors in the results of machine translation, please write to editor@tadviser.ru. We will make every effort to correct them as soon as possible. |